



“The role of nebulised budesonide in the treatment of exacerbations of COPD.”
H. Gunen, S.S. Hacievliyagil, O. Yetkin, G. Gulbas, L.C. Mutlu and E. In. *Eur Respir J* 2007; 29: 660–667.

A typographical error resulted in the mean blood glucose level at admission for patient group 2 being published as $116.4 \pm 37.8 \text{ mg} \cdot \text{dL}^{-1}$ in [table 1](#), when the correct value is $126.4 \pm 37.8 \text{ mg} \cdot \text{dL}^{-1}$. The corrected table is republished below.

TABLE 1 General characteristics of the patients at admission

	Group 1 [#]	Group 2 [¶]	Group 3 ⁺
Subjects n	39	40	42
Age years	63.5 ± 10.1	64.9 ± 7.1	63.9 ± 9.7
Males/females n	35/4	33/7	35/7
Disease duration years	11.1 ± 8.5	10.8 ± 5.6	10.8 ± 6.6
Smoking load pack-years	44.7 ± 19.5	43.4 ± 21.4	46.9 ± 21.7
Current smokers %	44	45	50
Haematocrit %	49.0 ± 6.1	48.9 ± 5.8	48.2 ± 6.5
Leukocyte count $10^9 \cdot \text{L}^{-1}$	$13\,355 \pm 5546$	$12\,715 \pm 5145$	$13\,605 \pm 5373$
BUN $\text{mg} \cdot \text{dL}^{-1}$	21.9 ± 9.4	24.9 ± 13.1	20.9 ± 8.8
Glucose $\text{mg} \cdot \text{dL}^{-1}$	114.0 ± 31.7	126.4 ± 37.8	114.3 ± 24.9
FVC % pred	64.5 ± 21.5	57.5 ± 17.7	64.3 ± 20.4
FEV1 % pred	36.7 ± 11.9	35.3 ± 11.7	39.6 ± 12.9
FEV1/FVC %	46.8 ± 15.9	48.4 ± 13.4	48.4 ± 13.2
FEF25–75% % pred	16.4 ± 7.8	15.7 ± 8.4	20.6 ± 16.1
pH	7.41 ± 0.09	7.41 ± 0.08	7.41 ± 0.09
SaO₂ %	83.6 ± 10.0	80.1 ± 12.4	79.9 ± 13.7
PaO₂ mmHg	52.4 ± 11.1	49.1 ± 12.6	50.1 ± 14.8
PaCO₂ mmHg	47.4 ± 16.7	51.4 ± 10.3	46.8 ± 12.7
Comorbidity index	1.55 ± 0.8	1.53 ± 0.7	1.56 ± 0.8

Data are presented as mean \pm SD, unless otherwise indicated. BUN: blood urea nitrogen; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; FEF25–75% mean forced expiratory flow between 25% and 75% of FVC; SaO₂: arterial oxygen saturation; PaO₂: arterial oxygen tension; PaCO₂: arterial carbon dioxide tension.
[#]: only bronchodilator; [¶]: systemic corticosteroid; ⁺: nebulised budesonide.